Modulation of murine lupus by Aconitate Decarboxylase 1

Abstract

Abstract Mitochondrial synthesis of itaconate by myeloid cells (monocytes and macrophages) is mediated by the TCA cycle enzyme Aconitate Decarboxylase 1 (Acod1). Upregulation of Acod1–itaconate pathway, occurs after activation of various Toll-like receptors (TLRs) or cytokine stimulation (TNF or type I Interferons). While various anti-inflammatory effects of the Acod1 – Itaconate pathway have been previously reported (e.g. decreases in IL-6 and IL-1β synthesis) the contribution of impairments in endogenous itaconate synthesis in systemic lupus erythematosus (SLE) remain poorly characterized. First, we explored and characterized Acod1 expression in bone marrow or monocyte-derived macrophages (BMDM and MDM, respectively) following in vitro imiquimod (IMQ) treatment. Then, we investigated the role of endogenous itaconate modulation in the development and severity of TLR-7 induced lupus using the IMQ model. 10-week-old wild type and Acod1 −/−mice were treated with topical IMQ cream for 5 weeks to induce an SLE phenotype. We found that Acod1 protein expression is induced in BMDM and MDM after 12 hours of IMQ stimulation, and this induction is partially dependent on IFNRa1 signaling. Moreover, Acod1 −/−BMDM treated with IMQ for 12 h displayed higher mRNA expression of il6, il1b, il18, ccl2, cxcl2, and cxcl9, together with an increase in pro-IL-1β protein levels. IL-6 and IL-1β production were also increased. After 5 weeks of in vivo IMQ topical treatment, Acod1 −/−mice have a higher concentration of circulating anti-dsDNA autoantibodies but a decrease in splenomegaly compared to the treated WT mice. These results, demonstrate a putative role for endogenous Acod1-itaconate pathway in the regulation of autoimmunity. This work is support by the NIH/NIAMS Intramural Research Program